secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTENSITY THERAPEUTICS, INC. (INTS)
CIK:        0001567264
Form:       8-K
Filed at:   2026-08-11T11:40:55+00:00
Accession:  0001567264-26-000061
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intensity Q2 2026 net loss $3.0M; resumes sarcoma and TNBC trials
-----------------------------------------------------------------

- Q2 2026 net loss $3.0M vs $2.5M in Q2 2025; R&D $1.8M, G&A $1.3M.
- Cash $9.5M at June 30; raised $1.6M net from ATM in Q2, $1.3M more after quarter end.
- Phase 3 INVINCIBLE-3 resumed enrollment activities in April 2026 after FDA-reviewed protocol amendment; 21 patients previously enrolled.
- Phase 2 INVINCIBLE-4 restarted treatment in July 2026; preliminary pCR 71% vs 42% for SOC; full enrollment targeted by end 2027.
- Opened first France site for INVINCIBLE-4; increased business development activities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1567264/000156726426000061/0001567264-26-000061-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1567264/000156726426000061/intensity-20260811.htm
  HTML page:      https://secwatch.observer/filing/0001567264-26-000061

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer